New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - pamidronic acid 12.63mg equivalent to 15 mg disodium pamidronate - solution for infusion - 15 mg/5ml - active: pamidronic acid 12.63mg equivalent to 15 mg disodium pamidronate excipient: mannitol phosphoric acid sodium hydroxide water for injection - treatment of conditions associated with increased osteoclast activity: · predominantly lytic bone metastases from breast cancer and advanced multiple myeloma

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - pamidronic acid 25.27mg equivalent to 30 mg disodium pamidronate - solution for infusion - 30 mg/10ml - active: pamidronic acid 25.27mg equivalent to 30 mg disodium pamidronate excipient: mannitol phosphoric acid sodium hydroxide water for injection - treatment of conditions associated with increased osteoclast activity: · predominantly lytic bone metastases from breast cancer and advanced multiple myeloma

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - pamidronic acid 50.54mg equivalent to 60 mg disodium pamidronate - solution for infusion - 60 mg/10ml - active: pamidronic acid 50.54mg equivalent to 60 mg disodium pamidronate excipient: mannitol phosphoric acid sodium hydroxide water for injection - treatment of conditions associated with increased osteoclast activity: · predominantly lytic bone metastases from breast cancer and advanced multiple myeloma

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - pamidronic acid 75.82mg equivalent to 90 mg disodium pamidronate - solution for infusion - 90 mg/10ml - active: pamidronic acid 75.82mg equivalent to 90 mg disodium pamidronate excipient: mannitol phosphoric acid sodium hydroxide water for injection - treatment of conditions associated with increased osteoclast activity: · predominantly lytic bone metastases from breast cancer and advanced multiple myeloma

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - flecainide acetate 100mg;   - tablet - 100 mg - active: flecainide acetate 100mg   excipient: croscarmellose sodium magnesium stearate maize starch microcrystalline cellulose pregelatinised maize starch purified water - in patients without structural heart disease and without myocardial infarction, flecainide bnm tablets are indicated for the prevention of: supraventricular arrhythmias · paroxysmal supraventricular tachycardias (psvt) including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms; · paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms. ventricular arrhythmias · documented life-threatening ventricular arrhythmias such as sustained ventricular tachycardia (vt) if they are considered life-threatening in the judgement of the attending physician. not indicated for less severe ventricular arrhythmias even if symptomatic. use of flecainide in chronic atrial fibrillation has not been adequately studied and is not recommended.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - flecainide acetate 50mg;   - tablet - 50 mg - active: flecainide acetate 50mg   excipient: croscarmellose sodium magnesium stearate maize starch microcrystalline cellulose pregelatinised maize starch - in patients without structural heart disease and without myocardial infarction, flecainide bnm tablets are indicated for the prevention of: supraventricular arrhythmias · paroxysmal supraventricular tachycardias (psvt) including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms; · paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms. ventricular arrhythmias · documented life-threatening ventricular arrhythmias such as sustained ventricular tachycardia (vt) if they are considered life-threatening in the judgement of the attending physician. not indicated for less severe ventricular arrhythmias even if symptomatic. use of flecainide in chronic atrial fibrillation has not been adequately studied and is not recommended.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - bupivacaine hydrochloride monohydrate 5.28 mg/ml equivalent to bupivacaine hydrochloride 5mg/ml - solution for injection - 0.5% w/v - active: bupivacaine hydrochloride monohydrate 5.28 mg/ml equivalent to bupivacaine hydrochloride 5mg/ml excipient: glucose monohydrate sodium hydroxide water for injection - bupivacaine spinal heavy bnm is indicated for · intrathecal (subarachnoid, spinal) anaesthesia for surgical and obstetrical procedures · lower abdominal surgery (including caesarean section), urological and lower limb, including hip surgery, lasting 1.5 to 3 hours.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - noradrenaline acid tartrate 2 mg/ml equivalent to 1 mg/ml noradrenaline base;   - concentrate for injection - 1 mg/ml - active: noradrenaline acid tartrate 2 mg/ml equivalent to 1 mg/ml noradrenaline base   excipient: nitrogen sodium chloride water for injection - for the restoration of blood pressure in certain acute hypotensive states (e.g. phaeochromocytomectomy, sympathectomy, poliomyelitis, spinal anaesthesia, myocardial infarction, septicaemia, blood transfusions and drug reactions). as an adjunct in the treatment of cardiac arrest. to restore and maintain an adequate blood pressure after an effective heartbeat and ventilation have been established by other means.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - ibuprofen 800mg - modified release tablet - 800 mg - active: ibuprofen 800mg excipient: colloidal silicon dioxide hypromellose opadry white 03a580003 povidone stearic acid xanthan gum - rheumatoid arthritis

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - tobramycin 300mg - solution for inhalation - 300 mg/5ml - active: tobramycin 300mg excipient: sodium chloride sodium hydroxide sulfuric acid water for injection - tobramycin bnm is indicated for the management of cystic fibrosis patients with p. aeruginosa infections. safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with fev1 <25% or >75% predicted, or patients colonised with burkholderia cepacia.